ScottSimonTykodiMDPhD

Associate Professor, Division of Medical Oncology, University of Washington Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center

Join to view full profile

Dr. Tykodi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Tykodi's full profile

Already have an account?

Office
Seattle Cancer Care Alliance
825 Eastlake Avenue, E
Seattle, WA 98109
Phone+1 206-606-2015
Is this information wrong?

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2000 - 2003
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1997 - 2000
Washington University in St. Louis School of MedicineClass of 1997

Certifications & Licensure

WA State Medical License 2000 - 2025

Clinical Trials

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer Start of enrollment: 2018 Aug 28
Terminated
Phase 1

Publications & Presentations

PubMed

Telemedicine for Multidisciplinary Urologic Cancer Care: A Prospective Single Institution Study.
Frederick Okoye, Adam J Gadzinski, Isabelle Abarro, Rishi Sekar, Petros Grivas, Scott S Tykodi, Jay Liao, Jonathan Chen, Jing Zeng, Jonathan Wright, John L Gore> ;Clinical Genitourinary Cancer. 2024 Feb 24
Single cell atlas of kidney cancer endothelial cells reveals distinct expression profiles and phenotypes.
Yuexin Xu, Chris P Miller, Jun Xue, Ying Zheng, Edus H Warren, Scott S Tykodi, Shreeram Akilesh> ;Research Square. 2023 Nov 10
Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip system.
Chris P Miller, Megan Fung, Carla A Jaeger-Ruckstuhl, Yuexin Xu, Edus H Warren, Shreeram Akilesh, Scott S Tykodi> ;Neoplasia. 2023 Dec 1
17 citations
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.
Toni K Choueiri, David F McDermott, Jaime Merchan, Todd M Bauer, Robert Figlin, Elisabeth I Heath, M Dror Michaelson, Edward Arrowsmith, Anishka D'Souza, Song Zhao, An...> ;The Lancet. Oncology. 2023 May 1
1 citations
Immunohistochemical Detection of 5T4 in Renal Cell Carcinoma.
Christopher P Miller, Farinaz Shokri, Shreeram Akilesh, Yuexin Xu, Edus H Warren, Scott S Tykodi, Maria Tretiakova> ;Applied Immunohistochemistry & Molecular Morphology. 2023 Mar 1
8 citations
A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive ne...
Evan E Gross, Mingjia Li, Ming Yin, Delaney Orcutt, Duncan Hussey, Elliot Trott, Sarah K Holt, Erin R Dwyer, Joel Kramer, Kaylee Oliva, John L Gore, George R Schade, D...> ;Urologic Oncology. 2023 Jan 1
Editorial: Immune checkpoint inhibitors in renal cell carcinoma.
Scott S Tykodi, Renate Pichler> ;Frontiers in Oncology. 2023 Jan 1
9 citations
CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review.
Andrew J Portuguese, Jordan Gauthier, Scott S Tykodi, Evan T Hall, Alexandre V Hirayama, Cecilia C S Yeung, Christopher D Blosser> ;Bone Marrow Transplantation. 2023 Apr 1
19 citations
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
Brian I Rini, Sabina Signoretti, Toni K Choueiri, David F McDermott, Robert J Motzer, Saby George, Thomas Powles, Frede Donskov, Scott S Tykodi, Sumanta K Pal, Saurabh...> ;Journal for Immunotherapy of Cancer. 2022 Dec 1
13 citations
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
Toni K Choueiri, Harriet Kluger, Saby George, Scott S Tykodi, Timothy M Kuzel, Ruth Perets, Suresh Nair, Giuseppe Procopio, Michael A Carducci, Vincent Castonguay, Edm...> ;Journal for Immunotherapy of Cancer. 2022 Nov 1
2 citations
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, ...
Daniel J George, David R Spigel, Lucio N Gordan, Samith T Kochuparambil, Ana M Molina, Jeff Yorio, Arash Rezazadeh Kalebasty, Heidi McKean, Nishan Tchekmedyian, Scott ...> ;BMJ Open. 2022 Sep 14
10 citations
Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.
Yuanquan Yang, Sarah P Psutka, Anish B Parikh, Mingjia Li, Katharine Collier, Abdul Miah, Sherry V Mori, Megan Hinkley, Scott S Tykodi, Evan Hall, John A Thompson, Min...> ;Cancer Medicine. 2022 Aug 1
14 citations
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma.
Nikos Kourtis, Qingqing Wang, Bei Wang, Erin Oswald, Christina Adler, Samvitha Cherravuru, Evangelia Malahias, Lance Zhang, Jacquelynn Golubov, Qiaozhi Wei, Samantha L...> ;Nature Cancer. 2022 Jul 1
16 citations
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Timothy A Yap, Justin F Gainor, Margaret K Callahan, Gerald S Falchook, Russell K Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T Gibney, Howard A Burris, Sco...> ;Clinical Cancer Research. 2022 Sep 1
2 citations
Associating sleep problems with advanced cancer diagnosis, and immune checkpoint treatment outcomes: a pilot study.
Arthur Sillah, Ulrike Peters, Nathaniel F Watson, Scott S Tykodi, Evan T Hall, Allison Silverman, Rachel C Malen, John A Thompson, Sylvia M Lee, Shailender Bhatia, Jos...> ;Supportive Care in Cancer. 2022 May 1
54 citations
Neoantigen-specific CD4T cells in human melanoma have diverse differentiation states and correlate with CD8T cell, macrophage, and B cell function.
Joshua R Veatch, Sylvia M Lee, Carolyn Shasha, Naina Singhi, Julia L Szeto, Ata S Moshiri, Teresa S Kim, Kimberly Smythe, Paul Kong, Matthew Fitzgibbon, Brenda Jeserni...> ;Cancer Cell. 2022 Apr 11
26 citations
Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review.
Andrew J Portuguese, Scott S Tykodi, Christopher D Blosser, Ted A Gooley, John A Thompson, Evan T Hall> ;Journal of the National Comprehensive Cancer Network. 2022 Apr 1
43 citations
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
Scott S Tykodi, Lucio N Gordan, Robert S Alter, Edward Arrowsmith, Michael R Harrison, Ivor Percent, Rakesh Singal, Peter Van Veldhuizen, Daniel J George, Thomas Hutso...> ;Journal for Immunotherapy of Cancer. 2022 Feb 1
1 citations
Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricte...
Yuexin Xu, Alicia J Morales, Andrea M H Towlerton, Shreeram Akilesh, Chris P Miller, Scott S Tykodi, Edus H Warren> ;Frontiers in Oncology. 2022 Jan 1
21 citations
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
Hamid Emamekhoo, Mark R. Olsen, Bradley Curtis Carthon, Alexandra Drakaki, Ivor John Percent, Ana M. Molina, Daniel C. Cho, Johanna C. Bendell, Lucio N. Gordan, Arash ...> ;Cancer. 2021 Nov 16
39 citations
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
Adi Diab, Scott S. Tykodi, Gregory A. Daniels, Michele Maio, Brendan D. Curti, Karl D. Lewis, Sekwon Jang, Ewa Kalinka, Igor Puzanov, Alexander I. Spira, Daniel C. Cho...> ;Journal of Clinical Oncology. 2021 Jul 13
9 citations
Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma.
Yuexin Xu, Chris P. Miller, Edus H. Warren, Scott S. Tykodi> ;Human Vaccines & Immunotherapeutics. 2021 Mar 5
75 citations
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.
David F McDermott, Jae-Lyun Lee, Marek Ziobro, Cristina Suarez, Przemyslaw Langiewicz, Vsevolod Borisovich Matveev, Pawel Wiechno, Rustem Airatovich Gafanov, Piotr Tom...> ;Journal of Clinical Oncology. 2021 Mar 20
58 citations
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.
David F McDermott, Jae-Lyun Lee, Georg A Bjarnason, James M G Larkin, Rustem A Gafanov, Mark D Kochenderfer, Niels Viggo Jensen, Frede Donskov, Jahangeer Malik, Alexan...> ;Journal of Clinical Oncology. 2021 Mar 20
1 citations
Predictive lifestyle markers for efficacy of cancer immune checkpoint inhibitors: a commentary.
Arthur Sillah, Scott S. Tykodi, Evan T. Hall, John A. Thompson, Nathaniel F. Watson, Sylvia Lee, Shailender Bhatia, Joshua R. Veatch, Jeannie Warner, Ulrike Peters, Ra...> ;Future Oncology. 2021 Jan 5
Join now to see all

Lectures

First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

ASCO GU 2021: Nivolumab plus Ipilimumab in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma (nccRCC): Safety and Efficacy from CheckMate 920February 13th, 2021
Vaccinia Virus and Immune Checkpoint Inhibitors: A Viable Combination in Advanced RCC?May 27th, 2020
ASCO Annual Meeting to Highlight Clinical Oncology Findings from Seattle Cancer Care Alliance (SCCA)May 21st, 2020
Join now to see all